Windhover Information's 2006 Therapeutic Alliance Series: Cardiovascular Conference.Most Promising Cardio Projects Will Present to Huge Audience Nov. 15-16, 2006, Chicago, IL NORWALK, Conn. -- Windhover Information's 2006 blockbuster partnering meeting, "Therapeutic Alliances: Cardiovascular Conference," a meeting point for business development and R&D that is focused strictly on cardiovascular technology, still has a few spaces available. The conference, the most efficient partnering meeting this year for the cardiovascular industry, is slated for Nov. 15-16 in Chicago, immediately following the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. conference. Online registrations are still being accepted at www.cardioalliances.com. Online partnering is now officially open. Registered attendees have access to Windhover's proprietary online, interactive partnering system, which enables participants to market their company and developments and engage in an ongoing dialogue with potential partners. Companies are therefore able to move quickly from identification of prospective partners to face-to-face meetings. Companies from the US, Switzerland, South Korea, Finland, Denmark, Canada, the United Kingdom and Germany are among those on the attendee list. Among the major players planning to attend are Boehringer Ingelheim, Genzyme Corp., Merck, Novartis, Orion Corp., Pfizer, The University of Pittsburgh and Wyeth. A complete list of attending companies to date is available at www.cardioalliances.com. Windhover's most promising projects The Top 10 Unpartnered Licensable Cardiovascular Projects list, developed by Windhover and Defined Health, is an eagerly-awaited feature of TA: Cardio. Presentations from the companies will include the product's target and first indication(s); other compounds addressing the same target; the relative advantage of the compound; the clinical results to date and general clinical plan for the future; IP on the compound or target; any partnerships currently held on the compound; and competitive advantage in the marketplace. The presenting companies to date are (listed in no specific order): * Proteo Biotech AG Compound: Elafin, a human protein that inhibits leukocyte leukocyte (l  `kəsīt'): see blood. leukocyte or white blood cell or white corpuscle elastase elastase /elas·tase/ (e-las´tas) see pancreatic elastase. e·las·tase n. An enzyme found especially in pancreatic juice that catalyzes the hydrolysis of elastin. and proteinase proteinase /pro·tein·ase/ (pro´ten-as?) endopeptidase. pro·tein·ase n. A protease that begins the hydrolytic breakdown of proteins usually by splitting them into polypeptide chains. 3. Elafin is produced in human skin, lungs and mammary gland mammary gland, organ of the female mammal that produces and secretes milk for the nourishment of the young. A mammal may have from 1 to 11 pairs of mammary glands, depending on the species. Generally, those mammals that bear larger litters have more glands. naturally. Elafin seems to protect cells against destruction by the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Inner organs, particularly muscles and vessels, do not contain Elafin, and therefore may be destroyed by the immune system, if affected by an inflammation. * ARYx Compound: ATI-2042, a proprietary compound in Phase 2 development for the treatment of atrial fibrillation (AFIB). ARYx has engineered ATI-2042 with the goal of developing a therapy equally effective but safer than the "gold standard" treatment, amiodarone. * Cytokinetics Compound: CK-1827452, a novel, small-molecule, direct activator of cardiac myosin myosin (mī`əsĭn), one of the two major protein constituents responsible for contraction of muscle. In muscle cells myosin is arranged in long filaments called thick filaments that lie parallel to the microfilaments of actin. . * Forbes Medi-Tech Inc. Compound: FM-VP4 (disodium ascorbyl phytosanyl phosphate), novel analogue of phytostanols which has demonstrated dramatic cholesterol-lowering and anti-atherosclerotic properties in pre-clinical trials. Study results showed that FM-VP4 was well tolerated and had significant LDL-lowering activity. * deCODE genetics Compound: DG 031, aimed at lowering risk of heart attack by inhibiting the activity of this pathway and reducing LTB LTB Lustiges Taschenbuch (German Disney comic) LTB Landlord and Tenant Board LTB Last Time Buy LTB Last Time Buy (purchasing) LTB Looking to Buy 4 production. * Isis Pharmaceutical Compound: ISIS 301012, a second-generation antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). inhibitor of apolipoprotein apolipoprotein /apo·lipo·pro·tein/ (ap?o-lip?o-pro´ten) any of the protein constituents of lipoproteins, grouped by function in four classes, A, B, C, and E. ap·o·lip·o·pro·tein n. B-100 (ApoB), which has demonstrated potent, prolonged dose-dependant reduction of ApoB, cholesterol, low-density lipoprotein (LDL-C LDL-C low-density-lipoprotein cholesterol ) and very low-density lipoprotein ver·y low-density lipoprotein n. Abbr. VLDL A lipoprotein containing a very large proportion of lipids to protein and carrying most cholesterol from the liver to the tissues. very low-density lipoprotein See VLDL. (VLDL VLDL very-low-density lipoprotein. ß-VLDL , beta VLDL a mixture of lipoproteins with diffuse electrophoretic mobility approximately that of ß-lipoproteins but having lower density; they are remnants derived from ) in Phase 1 trials. Triglyceride levels were also reduced. * Medicure Inc. Compound: MC 1, a potential treatment for blockages of blood to the heart (i.e. myocardial ischemia, associated with heart attacks, angina and arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of ) and the brain (i.e. ischemic stroke) and to prevent injury from ischemic reperfusion injury. * Surface Logix Compound: SLX SLX Student Loan Xpress SLX Smartlet Xml SLX Secure Links SLX Super Luxe 2101, an oral selective, fast-onset, long-acting (48 h) PDE-5 inhibitor designed specifically to expand the therapeutic potential of PDE-5 inhibition beyond erectile dysfunction into larger cardiovascular markets. * Viron Therapeutics Inc. Compound: VT 111, the first in a completely new class of therapeutic compounds for the treatment of inflammatory-based disorders. VT-111 will soon enter the clinic in its second indication, chronic organ rejection in transplant patients. In pre-clinical testing, VT-111 has shown a remarkable ability to reduce atherosclerosis and increase the stability of vulnerable plaques that can cause heart attacks; and the completed Phase I clinical study demonstrated a strong safety profile with no adverse events. Top cardio experts to share insights In addition to partnering and networking, attendees at TA: Cardio will be able to benefit from workshops and sessions led by industry leaders. The agenda includes: * Heart of the Matter: Key Issues and Opportunities in the Cardiovascular Drug Space with Michael Rice, Consultant, Defined Health * Translating Cardiovascular Advances into Prescribed Drugs moderated by Edward C. Saltzman, President, Defined Health, and with Dr. Richard Pasternak, Vice President of Clinical Research in Cardiovascular/Atherosclerosis, Merck and Co.; and Robert A. D. Scott, MD, Executive Vice President of Research & Development and Chief Medical Officer, AtheroGenics. * Trends, Valuations, and Success Rates in Cardiovascular Business Development: What Every Dealmaker deal·mak·er n. One that makes deals, as in business, finance, or politics. deal  mak Needs to Know with John Delyani, PhD, MBA MBAabbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration , Director, Strategic Alliances Cardiovascular Diabetes & Metabolism, Novartis Institutes for Biomedical Research * Workshop: Modeling your Market and Commercial Value for your Cardiovascular Drug * Workshop: Best Practices in Cardiovascular Clinical Trials The complete schedule to date is available at http://www.cardioalliances.com. Sponsorship opportunities available The Cardiovascular Alliances Conference is sponsored by DefinedHealth and Merck. Media sponsors are Business Wire, Cardiovascular Drug News and CanBiotech. Sponsorship opportunities can still be arranged by contacting Stefanie Greenberg at (203) 838-4401 x109 or sgreenberg@windhover.com. To register, contact Alexandria Riley at (203) 838-4401 ext. 113 or ariley@windhover.com; or register on the TA Cardiovascular Alliances Conference 2006 website at www.cardioalliances.com. About Windhover Information Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see www.windhover.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion